Near‐Infrared‐Light Remote‐Controlled Activation of Cancer Immunotherapy Using Photothermal Conjugated Polymer Nanoparticles
Source abstract
Abstract
Abstract Remote control of the therapeutic process is an ideal strategy for maximizing efficacy and avoiding side effects, especially for cancer immunotherapy. Herein, a conjugated polymer nanoparticles (CPNs)‐mediated optogenetic system for in situ activation of immunotherapy under near‐infrared laser irradiation is reported. This system is composed of photothermal CPNs and interferon‐gamma (IFN‐γ) plasmid driven by heat shock promoter HSP70. The photothermally responsive CPNs serve as a photo–heat nanotransducer to trigger the gene transcription of IFN‐γ cytokine. The secreted IFN‐γ from cancer cells can sufficiently elicit surrounding tumor‐associated macrophages activation through IFN‐γ‐JAK‐STAT1 transcription‐factor signaling pathway and finally induce cancer cell killing by immunotherapy. Therefore, this synergetic optogenetic system provides a promising approach to remotely control the process of cancer immunotherapy.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Photodynamic Therapy Research Studies · Cancer, Stress, Anesthesia, and Immune Response
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Beijing National Laboratory for Molecular Sciences Key Laboratory of Organic Solids Institute of Chemistry Chinese Academy of Sciences Beijing 100190 P. R. China
College of Chemistry University of Chinese Academy of Sciences Beijing 100049 P. R. China
Funding
National Natural Science Foundation of China
References (50)
Show source-provided references
1. 10.1016/j.immuni.2013.07.01210.1016/j.immuni.2013.07.012 ↗
2. 10.1038/nrc397310.1038/nrc3973 ↗
3. 10.1056/NEJMoa121513410.1056/NEJMoa1215134 ↗
4. 10.1038/mt.2010.2410.1038/mt.2010.24 ↗
5. 10.1126/science.aab407710.1126/science.aab4077 ↗
6. 10.1126/scitranslmed.aaf684310.1126/scitranslmed.aaf6843 ↗
7. 10.1038/nmat482210.1038/nmat4822 ↗
8. 10.1038/nnano.2017.5210.1038/nnano.2017.52 ↗
9. 10.1038/s41563-018-0028-210.1038/s41563-018-0028-2 ↗
10. 10.1038/s41467-017-01386-710.1038/s41467-017-01386-7 ↗
11. 10.1038/nnano.2017.11310.1038/nnano.2017.113 ↗
12. Alberts B. · 2009
13. 10.1038/nmeth.f.32410.1038/nmeth.f.324 ↗
14. 10.1111/dgd.1205310.1111/dgd.12053 ↗
15. 10.1021/acsnano.5b0638310.1021/acsnano.5b06383 ↗
16. 10.1038/nn.350210.1038/nn.3502 ↗
17. 10.1126/science.120353510.1126/science.1203535 ↗
18. 10.1038/nbt.341510.1038/nbt.3415 ↗
19. 10.1038/nmeth.353610.1038/nmeth.3536 ↗
20. 10.1002/smtd.20207002510.1002/smtd.202070025 ↗
21. 10.1073/pnas.190692911610.1073/pnas.1906929116 ↗
22. 10.1038/8668410.1038/86684 ↗
23. 10.1002/mabi.20190030110.1002/mabi.201900301 ↗
24. 10.1002/adfm.20180681910.1002/adfm.201806819 ↗
25. 10.1039/C4CS00011K10.1039/C4CS00011K ↗
26. 10.1002/adma.20130189010.1002/adma.201301890 ↗
27. 10.1021/acsabm.0c0139510.1021/acsabm.0c01395 ↗
28. 10.1039/D0QM00837K10.1039/D0QM00837K ↗
29. 10.1002/anie.20140716910.1002/anie.201407169 ↗
30. 10.1002/anie.20150553410.1002/anie.201505534 ↗
31. 10.1002/adma.20170541810.1002/adma.201705418 ↗
32. 10.1002/anie.20170554310.1002/anie.201705543 ↗
33. 10.1002/anie.20190926410.1002/anie.201909264 ↗
34. 10.1002/adfm.20180202610.1002/adfm.201802026 ↗
35. 10.1016/j.immuni.2019.06.00710.1016/j.immuni.2019.06.007 ↗
36. 10.1038/s41551-018-0254-610.1038/s41551-018-0254-6 ↗
37. 10.1021/acs.accounts.5b0033410.1021/acs.accounts.5b00334 ↗
38. 10.1002/adma.20130564510.1002/adma.201305645 ↗
39. 10.1002/adma.20120179510.1002/adma.201201795 ↗
40. 10.3762/bjoc.6.9210.3762/bjoc.6.92 ↗
41. 10.1016/j.colsurfb.2019.06.06610.1016/j.colsurfb.2019.06.066 ↗
42. 10.3390/colloids403002810.3390/colloids4030028 ↗
43. 10.1021/jp064341w10.1021/jp064341w ↗
44. 10.3390/vaccines202021610.3390/vaccines2020216 ↗
45. 10.34133/2021/981659410.34133/2021/9816594 ↗
46. 10.1021/acsami.7b1533210.1021/acsami.7b15332 ↗
47. 10.1039/C7NR07495F10.1039/C7NR07495F ↗
48. 10.1146/annurev.immunol.18.1.110.1146/annurev.immunol.18.1.1 ↗
49. 10.1016/j.coi.2003.11.00610.1016/j.coi.2003.11.006 ↗
50. 10.1038/s41577-018-0029-z10.1038/s41577-018-0029-z ↗